Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model by Wiedmann, F. et al.
Journal of the American Heart Association
J Am Heart Assoc. 2020;9:e015751. DOI: 10.1161/JAHA.119.015751 1
 
ORIGINAL RESEARCH
Pharmacologic TWIK-Related Acid-Sensitive 
K+ Channel (TASK-1) Potassium Channel  
Inhibitor A293 Facilitates Acute Cardioversion 
of Paroxysmal Atrial Fibrillation in a Porcine 
Large Animal Model
Felix Wiedmann, MD; Christoph Beyersdorf, BSc; Xiaobo Zhou, MD; Antonius Büscher, MD; Manuel Kraft, MSc; 
Jendrik Nietfeld, BSc; Teo Puig Walz, MSc; Laura A. Unger, MSc; Axel Loewe, PhD; Bastian Schmack, MD; 
Arjang Ruhparwar, MD; Matthias Karck, MD; Dierk Thomas, MD; Martin Borggrefe, MD; Gunnar Seemann, PhD; 
Hugo A. Katus, MD; Constanze Schmidt, MD
BACKGROUND: The tandem of P domains in a weak inward rectifying K+ channel (TWIK)- related acid- sensitive K+ channel 
(TASK- 1; hK2P3.1) two- pore–domain potassium channel was recently shown to regulate the atrial action potential duration. In 
the human heart, TASK- 1 channels are specifically expressed in the atria. Furthermore, upregulation of atrial TASK- 1 currents 
was described in patients suffering from atrial fibrillation (AF). We therefore hypothesized that TASK- 1 channels represent 
an ideal target for antiarrhythmic therapy of AF. In the present study, we tested the antiarrhythmic effects of the high- affinity 
TASK- 1 inhibitor A293 on cardioversion in a porcine model of paroxysmal AF.
METHODS AND RESULTS: Heterologously expressed human and porcine TASK- 1 channels are blocked by A293 to a similar 
extent. Patch clamp measurements from isolated human and porcine atrial cardiomyocytes showed comparable TASK- 1 cur-
rents. Computational modeling was used to investigate the conditions under which A293 would be antiarrhythmic. German 
landrace pigs underwent electrophysiological studies under general anesthesia. Paroxysmal AF was induced by right atrial 
burst stimulation. After induction of AF episodes, intravenous administration of A293 restored sinus rhythm within cardiover-
sion times of 177±63 seconds. Intravenous administration of A293 resulted in significant prolongation of the atrial effective re-
fractory period, measured at cycle lengths of 300, 400 and 500 ms, whereas the surface ECG parameters and the ventricular 
effective refractory period lengths remained unchanged.
CONCLUSIONS: Pharmacological inhibition of atrial TASK- 1 currents exerts antiarrhythmic effects in vivo as well as in silico, re-
sulting in acute cardioversion of paroxysmal AF. Taken together, these experiments indicate the therapeutic potential of A293 
for AF treatment.
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Atrial fibrillation (AF) is the most common sustained arrhythmia and represents a major risk factor for stroke, acute heart failure and cardiovascular 
morbidity.1 In the Western world, ≈2% of the population 
suffers from paroxysmal, persistent, or permanent AF. 
The prevalence and incidence of AF increase with age. 
It was predicted that the number of patients with AF 
will significantly rise in our aging population.2 Despite 
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the epidemiologic and individual relevance of AF, cur-
rent pharmacologic, interventional, or surgical thera-
peutic strategies show suboptimal effectiveness and 
frequently cause severe adverse events.3 Currently, 
safe and effective management of AF remains an 
unmet medical need.
Tandem of P domains in a weak inward recti-
fying K+ channel (TWIK)- related acid- sensitive K+ 
channel (TASK-1; K2P3.1) is a member of the two- 
pore–domain potassium (K2P- ) channel family. K2P 
channels are the most recently discovered family 
of K+ channels.4 The 15 members of the K2P fam-
ily are abundantly expressed throughout the body 
and are implicated in several physiological pro-
cesses, including the regulation of cardiac rhythm, 
blood pressure, neuroprotection, anesthesia, and 
apoptosis, as well as the sensation of oxygen ten-
sion, mechanical stress, taste, and temperature.5–9 
In cardiomyocytes, K2P channels mediate action 
potential repolarization. In particular, TASK- 1 cur-
rents were recently shown to modulate atrial action 
potential duration (APD) in AF and heart failure.10,11 
In the human heart, the expression of TASK- 1 sub-
units is restricted to the atria.10,12,13 Strikingly, the 
atrial TASK- 1 levels were upregulated in paroxysmal 
and chronic AF, which contributes to pathological 
shortening of the atrial APD.10 In vitro experiments 
demonstrated that pharmacologic blockade of 
TASK- 1 currents could revert the APD shortening 
observed in atrial cardiomyocytes isolated from pa-
tients with AF to levels observed among controls 
with sinus rhythm.10 Therefore, TASK- 1 inhibition 
may represent an atrial- specific, mechanism- based 
approach for AF therapy.14,15
The aromatic carbonamide A293 was initially de-
veloped as an inhibitor of the KV1.5 channel by Sanofi- 
Aventis (Frankfurt, Germany). This experimental 
compound was later found to be a much more potent 
TASK- 1 inhibitor that is active in the 3- digit nanomolar 
range.16–18
This preclinical study was designed as a proof- of- 
concept trial to assess the antiarrhythmic potential of 
the pharmacologic TASK- 1 K+ channel inhibitor A293 
for acute cardioversion in a porcine model of AF as 
well as in a translational in silico model of human atrial 
electrophysiology.
METHODS
Data, Materials, and Code Disclosure 
Statement
The data that support the findings of this study are 
available from the corresponding author upon request.
Ethics Statement
The study protocol involving human tissue sam-
ples was approved by the ethics committees of the 
University of Heidelberg (Germany; Medical Faculty 
Heidelberg, S- 017/2013; Medical Faculty Mannheim, 
2011- 216 N- MA). Written informed consent was ob-
tained from all patients, and the study was conducted 
in accordance with the Declaration of Helsinki. Animal 
experiments were carried out in accordance with the 
Guide for the Care and Use of Laboratory Animals 
as adopted and promulgated by the US National 
Institutes of Health (NIH publication no. 86- 23, re-
vised 1985), with European Union Directive 2010/63/
EU, and with the current version of the German 
Law on the Protection of Animals. Approval for ex-
periments involving animals was granted by the local 
Animal Welfare Committee (Regierungspraesidium 
CLINICAL PERSPECTIVE
What Is New?
• Tandem of P domains in a weak inward rectify-
ing K+ channel (TWIK)-related acid-sensitive K+ 
channel (TASK-1) background potassium chan-
nels, which were recently described to be up-
regulated in patients with atrial fibrillation display 
comparable atrial-specific expression patterns 
in the human and the porcine heart.
• Our preclinical in vivo study shows that pharma-
cological inhibition of TASK-1 can be employed 
for fast and safe cardioversion of new-onset 
atrial fibrillation episodes.
What Are the Clinical Implications?
• TASK-1 inhibition might extend our options for 
pharmacological atrial fibrillation therapy.
• Atrial-specific antiarrhythmic effects of TASK-1 
inhibition lack proarrhythmogenic ventricular 
side effects.




AERP atrial effective refractory period
AF atrial fibrillation
APD action potential duration
BCL basic cycle length
K2P two-pore–domain potassium channel
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Karlsruhe, Germany, reference numbers A- 38/11, 
 G- 221/12, G- 296/14, and G- 217/18).
Animal Handling
Electrophysiological studies were performed in 17 
anesthetized pigs of both sexes (<6  months of age; 
body weight 30–45 kg). After sedation with azaperon 
(5  mg/kg IM; Elanco, Bad Homburg, Germany), mi-
dazolam (1  mg/kg IM; Hameln Pharma Plus GmbH, 
Hameln, Germany), and ketamine (10  mg/kg IM; 
Zoetis Deutschland GmbH, Berlin, Germany), animals 
were anesthetized with propofol (1.5  mg/kg IV bolus 
followed by 4–8  mg/kg/h IV; Fresenius Kabi, Bad 
Homburg, Germany). For analgesia, buprenorphine 
(0.02  mg/kg IV; Bayer Vital GmbH Tiergesundheit, 
Leverkusen, Germany) was administered. Mechanical 
ventilation was performed using the Draeger Primus 
system (Draeger, Luebeck, Germany). Before surgical 
jugular vein preparation, a single dose of cefuroxime 
was administered (750 mg IV; Ratiopharm GmbH, Ulm, 
Germany). No volatile anesthetics were used to avoid 
pharmacologic interaction with cardiac K2P channels. 
Pigs were kept under specific pathogen- free condi-
tions at a room temperature of 20°C±2°C with a maxi-
mum housing density according to directive 2010/63/
EU. Room lighting had a light/dark cycle of 12/12  h. 
Water was offered ad libitum and pigs were fed twice 
a day with balanced complete feed (SAF 130M, ZG 
Raiffeissen, Karlsruhe, Germany). Environmental en-
richment was provided with biting woods, chains, and 
feeding balls.
Electrophysiological Examination
After cannulation of the right jugular vein, quadripo-
lar catheters were placed under fluoroscopic guid-
ance at the junction of the superior vena cava to the 
right atrium and in the right ventricular apex. A UHS 
20 stimulus generator (Biotronik, Berlin, Germany) was 
used for intracardiac stimulation and the EP Lab duo 
system (Bard Electrophysiology Division, Lowell, MA) 
was used for recording, analyzing, and storing ECGs. If 
induction of AF episodes required electrical cardiover-
sion, electrophysiological studies were paused for at 
least 30 minutes afterwards.
Pacing thresholds ranged from 0.5 to 2 V at 2.9 ms, 
and stimulation was performed at twice the diastolic 
pacing threshold. For measurements of effective re-
fractory periods, a conditioning train of 9 basic stim-
uli (S1) was followed by a diastolic extrastimulus (S2) 
starting 150  ms longer than the expected effective 
refractory period. Coupling intervals of extrastimuli 
were decreased in 10- ms decrements until refracto-
riness of the S2 stimulus was achieved. The shortest 
coupling interval eliciting a propagated atrial re-
sponse was taken as the effective refractory period. 
Surface ECGs were recorded using conventional 
adhesive electrodes (3M red dot, 3M, Maplewood, 
MN) in the classical Einthoven /Goldberger /chest- 
lead configurations, and QT intervals were corrected 
using Bazett’s formula.19
Porcine Model of Acute Paroxysmal AF
AF was induced via right atrial burst stimulation (2- to 
8- second bursts, at 400/min to 1200/min, 10 V, 2.9 ms 
duration). Upon induction of AF episodes, atrial rhythm 
was monitored for 5 minutes to probe stability of the 
AF episode. Pigs that still remained in AF after this 
5- minute period were subjected to treatment with A293 
or respective vehicle controls. Time to conversion was 
monitored. When a pig remained in AF >10 minutes, 
an electrical cardioversion was performed. No further 
pharmacologic experiments were performed on indi-
vidual animals for at least 8 plasma half- life times of 
A293.
Drug Administration
The aromatic carbonamide A293 2- (butylsulfon
ylamino)- N- [(1R)- 1- (6- methoxy- 3- pyridyl)propyl]- 
benzamide synthesized by ChiroBlock (ChiroBlock, 
Wolfen, Germany) with a purity of 98%, was dis-
solved in dimethyl sulfoxide to a concentration of 
10 mmol/L and stock solutions were stored at - 20°C. 
During experiments, 1 mg/kg body weight of A293 
was administered as short infusion (100  mL 0.9% 
NaCl) over 5 minutes.
Cardiomyocyte Isolation and Patch Clamp 
Measurements
After transport in chilled Ca2+- free solution 
(100  mmol/L NaCl, 10  mmol/L KCl, 1.2  mmol/L 
KH2PO4, 5  mmol/L MgSO4, 50  mmol/L tau-
rine, 5  mmol/L 3- (N- morpholino)propanesulfonic 
acid, 30  mmol/L 2,3- butanedione monoxime and 
20 mmol/L glucose, pH 7.0 with NaOH), right atrial 
human or porcine tissue samples were dissected 
into small chunks and rinsed 3 times for 3 minutes 
with Ca2+-free Tyrode’s solution. All solutions were 
oxygenated with 100% O2 at 37°C. Subsequently, 
tissue pieces were subjected to digestion with col-
lagenase type I, 288 U/mL (Worthington Biochemical 
Corporation, Lakewood, NJ) and protease type XXIV, 
5  mg/mL (Sigma- Aldrich) in Ca2+- free Tyrode’s so-
lution for 15  minutes. The Ca2+ concentration was 
then increased to 0.2  mmol/L, and the tissue was 
stirred for an additional 35 minutes in protease- free 
solution until rod- shaped single atrial myocytes were 
released. The cell suspension was centrifuged, and 
cardiomyocytes were resuspended in a storage solu-
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glucose, 70  mmol/L K glutamate, 10  mmol/L β- 
hydroxybutyrate, 10 mmol/L taurine, 10 mmol/L ethyl-
ene glycol tetraacetic acid, 1% albumin). Patch clamp 
measurements were performed in whole cell config-
uration at room temperature (21–25°C) using either 
a RK- 400 (Bio- Logic SAS, Seyssinet- Pariset, France) 
or an Axoptach 200B amplifier (Molecular Devices 
LLC, San José, CA). Glass pipettes were pulled 
from borosilicate glass (1B120F- 4; World Precision 
Instruments, Berlin, Germany). After back- filling 
with internal solution (60 mmol/L KCl, 65 mmol/L K 
glutamate, 3  mmol/L K2ATP, 0.2  mmol/L Na2GTP, 
2 mmol/L MgCl2, 5 mmol/L ethylene glycol tetraacetic 
acid, 5  mmol/L 4- (2- hydroxyethyl)piperazine- 1- 
ethanesulfonic acid (HEPES), pH adjusted to 7.2 with 
potassium hydroxide) tip resistances ranged from 3 
to 4 MΩ. Cardiomyocytes subjected to background 
potassium current recordings were constantly su-
perfused with an extracellular solution (140 mmol/L 
NaCl, 5.4  mmol/L KCl, 1  mmol/L MgCl2, 1  mmol/L 
CaCl2, 0.33  mmol/L NaH2PO4, 5  mmol/L HEPES, 
10  μmol/L tetrodotoxin, 1  μmol/L nifedipine, and 
10 mmol/L glucose, pH adjusted to 7.4 with NaOH). 
Seal resistances yielded 4 to 8 GΩ. Series resistance 
and cell capacitance were compensated. Data were 
not corrected for liquid junction potentials. Membrane 
currents were evoked by application of voltage steps 
between −60 and +60  mV in 10- mV increments 
(duration, 400  ms; holding potential, −50  mV) as 
depicted. Patch pipettes for cardiac action poten-
tial recordings were filled with 134 mmol/L K gluco-
nate, 6 mmol/L NaCl, 1.2 mmol/L MgCl2, 1 mmol/L 
MgATP, 10 mmol/L HEPES, pH adjusted to 7.2 with 
potassium hydroxide. Extracellular Tyrode’s solution 
was composed of 137  mmol/L NaCl, 5.4  mmol/L 
KCl, 2 mmol/L CaCl2, 1 mmol/L MgSO4, 10 mmol/L 
glucose and 10 mmol/L HEPES, pH 7.3 with NaOH. 
Action potentials were elicited in current clamp mode 
with a holding current of −40 pA by injection of brief 
current pulses (2 ms, 1 nA) at 0.2 Hz stimulation rate.
Molecular Biology and Xenopus Oocyte 
Electrophysiology
Plasmid constructs containing cDNA encoding human 
TASK- 1 (GenBank accession no. NM_002246) cloned 
in the expression vector pRAT were kindly provided by 
Steve Goldstein (Brandeis University, Waltham, MA). 
The pMAX–pTASK- 1 construct, encoding for porcine 
TASK- 1 (KF182337.1), was cloned from porcine cardiac 
cDNA, as described earlier.14 In vitro synthesis of copy 
RNA was performed using the mMESSAGE mMA-
CHINE T7 Transcription Kit (Thermo Fisher Scientific, 
Waltham, MA) according to the manufacturer’s instruc-
tions, as described earlier.20 Integrity of transcripts 
was assessed via agarose gel electrophoresis and 
concentration was determined by spectrophotometry 
(ND- 2000, Thermo Fisher Scientific). For oocyte prepa-
ration, ovarian lobes were surgically removed in aseptic 
techniques from female Xenopus laevis frogs (Xenopus 
Express, Le Bourg, France), anesthetized with tric-
aine solution (1  g/L, pH 7.5, 15°C). Frogs were kept 
in specific pathogen- free aquarium facilities with con-
tinuous water flow (Aqua Schwarz GmbH, Göttingen, 
Germany) at a housing density according to directive 
2010/63/EU. Water temperature was kept at 18°C and 
room lighting had a light/dark cycle of 12/12 h. Frogs 
were fed daily with food extrudate 3590.ES.F10 (Kliba 
Nafag, Kaiseraugst, Switzerland) and environmental 
enrichment was provided with huts and polyvinyl chlo-
ride pipes. No more than 4 operations were performed 
on 1 individual frog.
After collagenase treatment, stages V and VI de-
folliculated oocytes were manually selected under a 
stereo microscope and injected with 1.5 to 25 ng of 
cRNA. Two- electrode voltage clamp recordings of 
macroscopic currents were performed, as reported 
earlier.18 In brief, measurements were performed 1 
to 4  days after cRNA injection using a Warner OC- 
725C amplifier (Warner Instruments, Hamden, CT) 
and pCLAMP9 (Axon Instruments, Foster City, 
CA) software for data acquisition. Electrodes were 
pulled from borosilicate glass (GB 100F- 10, Science 
Products, Hofheim, Germany) using a Flaming/Brown 
P- 87 micropipette puller (Sutter Instruments, Novato, 
CA). After back- filling with 3 M of KCl, tip resistances 
yielded 1 to 2.5 mOhm. All recordings were performed 
at room temperature (20–22°C) in a standard physio-
logical extracellular solution, consisting of: 96 mmol/L 
NaCl, 4 mmol/L KCl, 1.1 mmol/L CaCl2, 1 mmol/L 
MgCl2, and 5 mmol/L HEPES (pH 7.4). TASK- 1 cur-
rents were evoked by application of 500- ms test 
pulses from −80 to +60 mV in 20- mV increments from 
a holding potential of −80 mV. Leak currents were not 
subtracted.
Tissue Handling and Quantitative 
Real- Time Polymerase Chain Reaction 
Expression Analysis
Tissue samples of right or left atrial appendages were 
obtained from patients undergoing open heart sur-
gery for coronary artery bypass grafting or valve repair 
or replacement. Left ventricular tissue samples were 
acquired from patients with ischemic or dilated cardi-
omyopathy during left ventricular assist device implan-
tation. Porcine hearts were extracted after intracardiac 
injection of KCl in deep anesthesia, rinsed in phos-
phate buffered saline and quickly dissected. Tissue 
samples were flash- frozen in liquid nitrogen and stored 
at −80°C, and RNA isolation was performed using 
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to the manufacturer’s protocol. RNA concentration 
was quantified via nanodrop spectrophotometry, 
and synthesis of single- stranded cDNA was carried 
out using the Maxima First Strand cDNA Synthesis 
Kit (Thermo Fisher Scientific) with 3 μg of total RNA 
per 20 μL reaction. Quantitative real- time polymerase 
chain reaction was carried out as reported.21 In brief, 
10 μL per reaction, consisting of 0.5 μL cDNA, 5 μL 
TaqMan Fast Universal Master Mix (Thermo Fisher 
Scientific), and 0.5  μL 6- carboxyfluorescein (FAM)- 
labeled TaqMan probes and primers (TaqMan Gene 
Expression Assays; Thermo Fisher Scientific) were 
analyzed using the StepOnePlus (Applied Biosystems, 
Foster City, CA) PCR system. Importin 8 (IPO8, HS 
00183533_m1; Thermo Fisher, Darmstadt, Germany) 
as well as beta-actin (ACTB, Ss03376081_u1; Thermo 
Fisher Scientific) housekeeping genes were used for 
normalization of signals of KCNK3 mRNA encoding 
TASK- 1 (Hs00605529_m1; Thermo Fisher Scientific). 
All quantitative real- time polymerase chain reactions 
were performed as triplicates and control experi-
ments in the absence of cDNA were included. Means 
of triplicates were used for calculating 2−ΔCt, the ratio 
of mRNA expression versus respective housekeeping 
genes.
Homology Model and Docking Simulation
Three- dimensional open- state structure models of 
pTASK- 1 channels were calculated on the basis of the 
crystal structure of hTREK- 1 (PDB ID: 6CQ8)22 using 
the SWISS- MODEL platform.23–26 For visualization of 
A293 in the pTASK- 1 central cavity, molecular docking 
calculations were performed using AutoDock Vina.27 
Polar hydrogens and Kollmann charges were added 
using AutoDockTools 1.5.6.28 The cubic grid box had 
an axial length of 35 Å and was centered on the intra-
cellular central channel cavity, where the binding site 
of A293 in human TASK- 1 had been identified earlier.18 
Docking simulations were performed with potassium 
ions in positions S1 and S3 within the selectivity filter 
of TASK- 1. Three- dimensional visualizations of in silico 
simulations and dockings were generated with PyMOL 
1.8 (PyMOL Molecular Graphics System, Schrödinger, 
LLC, New York, NY).
Computational Simulations
The computational description of the influence of 
TASK- 1 channel inhibition on atrial reentry behav-
ior is based on the Courtemanche–Ramirez–Nattel 
model of human atrial electrophysiology29 in conjunc-
tion with a description of the K2P channel.
10 To avoid 
long- term drift of the Courtemanche–Ramirez–Nattel 
model,30 concentrations of intracellular sodium ([Na+]i) 
and potassium ([K+]i) were kept constant. The channel 
conductivity of IK1 and IKur were adjusted (in line with 
Schmidt et  al10) to represent the measured atrial ef-
fective refractory periods (AERPs) at the basic cycle 
length (BCL) of 300, 400, and 500  ms (see Results) 
including A293: gK1 and gKur were increased by 62.5% 
and 50%, respectively. The parameters of the TASK- 1 
model were then adjusted to reconstruct the measured 
AERPs without A293 at the BCLs: the TASK- 1 conduc-
tivity for AF cells was set to 0.0035 nS/pF to simulate 
the state without drug bound to the channel. For all 
simulations, the CARPentry monodomain software 
was used with a time step of 10 microseconds using 
the Crank–Nicolson method in conjunction with mass 
lumping.31 To predict the A293 dose- dependent pro-
longation of APD in a single- cell environment, we used 
the Hill equation with an IC50 value of 100 nmol/L
16 and 
a Hill coefficient of 1. Dose- response curves were cal-
culated for a BCL of 200, 300, 500, and 1000 ms. The 
APD at 90% repolarization (APD90) of the 100th beat 
was evaluated to allow adaptation of the simulated sys-
tem to BCL and drug dose.
The effect of TASK- 1 channel blockade on atrial 
arrhythmia is shown in a simplified left atrial geome-
try.32 This consists of a 2- dimensional sphere surface 
with a diameter of a standard human left atrium (5 cm) 
and 5 orifices representing the 4 pulmonary veins as 
well as the mitral valve. The model has an average 
edge length of the underlying tetrahedra of 0.5 mm 
and is homogeneous and isotropic to keep it as sim-
ple as possible to neglect interindividual differences. 
In all simulations, the cell states were adjusted to a 
BCL of 300 ms according to single- cell results after 
50 stimulations. Additionally, on the basis of 1- phase 
singularity (center point of a rotor), the cell states 
were adjusted to start the simulation with 1 rotor at a 
given location.32,33 The initial rotor was simulated for 
10 seconds with different tissue conductivities and 
thus conduction velocities. Additional 5 seconds for 
each conductivity were calculated for both blocked 
and unblocked TASK- 1 channels. We investigated in 
which range of tissue conductivities A293 was able 
to eliminate the rotor.
Statistical Analysis
PCLAMP 10 (Axon Instruments, Foster City, CA), 
Origin 8 (OriginLab, Northampton, MA), Prism 8 
(GraphPad, La Jolla, CA), and Excel (Microsoft, 
Redmond, WA) software was used for data ac-
quisition and analysis. Data are expressed as 
mean±SEM. Nonparametric Kruskal–Wallis tests, 
Mann–Whitney tests, or Wilcoxon matched- pairs 
tests were applied to compare the statistical signifi-
cance in cases of small sample sizes where the as-
sumption of normality would be difficult to assess. If 
the hypothesis of equal means could be rejected at 
the 0.05 level, pairwise comparisons of groups were 
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multiple comparisons using the Bonferroni correc-
tion. In situations with sample sizes of <5, Student t 
tests were used instead of nonparametric tests and 
normal distribution was assessed with Anderson–
Darling tests.
RESULTS
Homology of Human and Porcine TASK- 1 
Orthologs and Atrial Specific Tissue 
Expression
The pig represents an established and clinically rel-
evant large animal model for AF. Major anatomic and 
physiological analogies to humans constitute specific 
advantages of pigs compared with rodents, zebrafish, 
or other commonly used small animal models. To as-
sess whether the pig would be suitable for studying 
the role of TASK- 1 channels in atrial electrophysiology, 
we performed structural and functional comparisons 
of porcine and human TASK- 1 channels. Cloning and 
functional characterization of the porcine TASK- 1 or-
thologs was described earlier.14 Amino acid sequence 
alignments of pTASK- 1 and hTASK- 1 showed 96.7% 
conservation at the protein level (Figure  1A). While 
the transmembrane regions were found to be highly 
conserved between hTASK- 1 and pTASK- 1, minor dif-
ferences were found for the N- and C- termini of the 
channel protein. One single amino acid substitution 
(H180T) is located within the third transmembrane do-
main (M3) at a distance of 20 amino acid residues to 
the selectivity filter motif of the second pore- forming 
loop (Figure 1A).
In the human heart, TASK- 1 channels are specifi-
cally expressed in the atria, whereas ventricular TASK- 1 
expression levels are virtually negligible.10,12,13 Real- time 
quantitative real- time polymerase chain reaction exper-
iments showed that subcompartment- specific patterns 
of KCNK3 mRNA levels in the porcine heart are similar 
to expression patterns in the human heart. Abundant 
expression was observed in the left atrial appendages 
as well as in the right atrial appendages, while expres-
sion in left ventricular tissue was low (Figure 1B).
Inhibition of Heterologously Expressed 
TASK- 1 Potassium Channels by A293
Human and porcine TASK- 1 channel subunits that 
were heterologously expressed in Xenopus laevis 
oocytes gave rise to comparable macroscopic cur-
rents (Figure  1C). Forty- eight hours after injection 
of RNA encoding either human or porcine TASK- 1 
orthologs, Xenopus laevis oocytes were sub-
jected to two- electrode voltage clamp measure-
ments. Outward potassium currents were elicited 
by application of the pulse step protocol depicted in 
Figure 1C. Depolarizing test pulses of 500 ms were 
applied in +20- mV increments from a holding poten-
tial of −80 mV to +60 mV at a frequency of 0.2 Hz. 
The measurements were repeated every 2 minutes. 
Upon administration of the high- affinity TASK- 1 inhibi-
tor A293 (100 μmol/L) into the extracellular solution, 
a rapid current decline to 21.3±8.7% (n=3, hTASK- 1) 
and 28.0±6.8% (n=3, pTASK- 1) of the control currents 
was observed (Figure  1C). These findings suggest 
that the structural similarities between porcine and 
human TASK- 1 channels are linked to comparable 
pharmacologic characteristics. Next, we used in silico 
docking simulations to predict how the A293 mole-
cule binds to the inner pore of the pTASK- 1 channels 
and thereby occludes the passage of potassium ions 
through the channel selectivity filter. Figure 1D visual-
izes the simulated docking of A293 to hTASK- 1. The 
docking site is near the pore- lining amino acids L239 
and N240. Recently, it was experimentally shown that 
these amino acids are indeed part of the molecular 
binding site of A293 at hTASK- 1.18
Comparison of TASK- 1 Currents in Porcine 
and Human Atrial Cardiomyocytes
To further assess whether similar functional proper-
ties and cardiac expression patterns of the human 
Figure 1. Structural and functional comparison of human and porcine TASK- 1 channels.
A, Left panel: Amino acid alignments of pTASK- 1 and hTASK- 1 show high similarity between human and porcine orthologs at the protein 
level. Differences are highlighted in red (*, conserved amino acids; :, amino acid substitutions by residues with similar properties). 
Right panel: Differences between human and porcine TASK- 1 are highlighted in a 3- dimensional structure homology model of 
pTASK- 1 in red color. C- termini were truncated because of lack of template sequences. B, Real- time quantitative polymerase chain 
reaction experiments revealed similar atrial specific TASK- 1 expression patterns in human and porcine cardiac tissue. KCNK3 mRNA 
expression is presented relative to the housekeeping genes importin 8 (IPO8) or β- actin (ACTB) in left atrial appendages (LAA), right 
atrial appendages (RAA) and the anterior wall of the left ventricle (LV) (n=5). C, Cloned human and porcine TASK- 1 ion channel subunits, 
heterologously expressed in Xenopus laevis oocytes, are inhibited by A293 (100 μmol/L) to a similar extent. Currents were recorded 
using two- electrode voltage clamp technique measurements after application of the depicted pulse protocol. Quantification was 
performed at the end of the +20 mV pulse (n=3 cells). Representative current traces of hTASK- 1 and pTASK- 1 before (Control) and after 
application of A293 (100 μmol/L, 30 min) are indicated on the right side. Scalebars are given as inserts. D, In silico docking simulation 
of A293 in the inner channel pore of a pTASK- 1 homology model and magnified excerpts illustrate the interactions of A293 with the 
pore lining amino acids I118, L239 and N240. Data are presented as mean±SEM. **P<0.01 in Mann–Whitney tests. TASK- 1 indicates 
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and porcine TASK- 1 channels result in comparable 
TASK- 1 currents at the single- cell level, we subjected 
isolated atrial human and porcine cardiomyocytes to 
patch clamp measurements. The human atrial car-
diomyocytes were derived from patients with sinus 
rhythm without a prior history of AF episodes and 
without relevant left ventricular dysfunction.
Background potassium currents were evoked by 
the application of voltage steps between −60 and 
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of −50 mV (Figure 2A and 2B). The TASK- 1 currents 
were isolated by application of A293 (200  nmol/L) 
as reported previously.10,11 The current- voltage rela-
tionships of the background potassium currents be-
fore and after administration of A293 are depicted in 
Figure 2C and 2D (human cardiomyocytes: n=16 cells 
obtained from N=6 individuals; porcine cardiomyo-
cytes: n/N=8/4). While human atrial cardiomyocytes 
displayed slightly higher background potassium cur-
rent densities at the baseline level, administration of 
A293 (200 nmol/L) resulted in comparable current in-
hibition (Figure 2E). The calculated A293- sensitive K+ 
current densities were activated at potentials >−20 mV 
and showed Goldman- Hodgkin- Katz rectification, 
which is typical for K2P channels (Figure 2F). In porcine 
cardiomyocytes, the TASK- 1 current density quanti-
fied at +40 mV reached 68% of the currents obtained 
from isolated human atrial cardiomyocytes (human: n/
N=16/6; porcine: n/N=8/4, Figure 2G). Representative 
micrographs of isolated human and porcine atrial car-
diomyocytes are presented in Figure 2H.
Effects of TASK- 1 Current Inhibition on 
the APDs of Porcine and Human Atrial 
Cardiomyocytes
Atrial APs were studied under current- clamp condi-
tions in human and porcine atrial cardiomyocytes, and 
the TASK- 1 currents were again isolated via application 
of A293 (Figure 2I and 2J). In human atrial cardiomyo-
cytes, administration of A293 (200 nmol/L) prolonged 
the APD at 50% repolarization (APD50) by 6% and the 
APD90 by 18% (n/N=9/5; pAPD50=0.0087; pAPD90=0.009; 
Wilcoxon matched- pairs test), while in porcine cardio-
myocytes, prolongations of the APD50 by 19% and the 
APD90 by 24% were observed (n/N=5/4; pAPD50=0.81; 
pAPD90=0.63; Wilcoxon matched- pairs test; Figure 2K 
and 2L).
Taken together, the functional similarities be-
tween the porcine and human TASK- 1 channels 
and the comparable cardiac expression patterns 
indicate that the pig represents an adequate model 
for studying the role of TASK- 1 currents in cardiac 
electrophysiology.
Effects of A293 on Surface ECG 
Parameters
To assess the effects of TASK- 1 inhibition by A293 on 
cardiac electrophysiology, we recorded the surface 
ECGs from anesthetized pigs before and after applica-
tion of A293. Five healthy male German landrace pigs 
with a body weight of 30 to 45 kg were anesthetized, 
and 1 mg/kg body weight of A293 was administered 
as an intravenous short infusion. No significant differ-
ences in surface ECG parameters upon A293 treat-
ment were observed (Figure 3).
TASK- 1 Inhibition by A293 Selectively 
Prolongs the Atrial Effective Refractory 
Periods
AERPs were assessed through invasive electrophysi-
ological studies. AERPs, measured at different BCLs, 
were significantly prolonged upon TASK- 1 inhibition by 
A293 (Figure 4A through 4H). Vascular access after sur-
gical jugular vein preparation and fluoroscopic place-
ment of quadripolar diagnostic catheters is visualized in 
Figure 4A and 4B. AERP measured at a BCL of 500 ms 
(AERP500) was shifted by 20 ms from 200±4.1 ms under 
control conditions to 220±4.1 ms after intravenous infu-
sion of A293 (P=0.016; n=4 pigs; Figure 4C). AERP400 was 
prolonged by 22.5 ms from 175±9.6 ms to 197.5±9.5 ms 
after TASK- 1 inhibition by (P=0.037; Student t test; n=4 
pigs; Figure 4E), and AERP300 was prolonged by 17.5 ms 
from 155±13.2 ms to 172.5±13.1 ms under A293 treat-
ment (P=0.006; n=4 pigs; Figure 4G).
In addition, the ventricular effective refractory pe-
riods at different BCLs remained unchanged after 
intravenous A293 treatment (Figure  4D and 4F), 
demonstrating atrial- specific class III antiarrhythmic ef-
fects of A293 (Figure 4H). Furthermore, no proarrhyth-
mic effects under A293 treatment were  observed while 
performing programmed ventricular stimulation.
Figure 2. Comparison of TASK- 1 currents in human and porcine atrial cardiomyocytes.
A and B, Representative background potassium currents, recorded from isolated human (A) or porcine (B) cardiomyocytes under 
control conditions (CTRL) and after administration of the high affinity TASK- 1 channel inhibitor A293, 200 nmol/L (A293). Dashed lines 
represent zero current level. The pulse protocol is depicted at the right bottom corner of panel (B). C and D, Corresponding mean step 
current densities are displayed as a function of the respective test potentials for human (C) and porcine (D) cardiomyocytes (human 
cardiomyocytes: n=16 cells obtained from N=6 individuals; porcine cardiomyocytes: n/N=8/4). E, Comparison of mean current density, 
quantified at +40 mV membrane potential. F, Current- voltage relationships of mean A293- sensitive current densitiy are displayed for 
human (blue) and porcine (red) atrial cardiomyocytes (human: n/N=16/6, porcine: n/N=8/4). G, Comparison of mean A293- sensitive 
current densitiy measured at a membrane potential of +40 mV (human: n/N=16/6, porcine: n/N=8/4). H, Micrographs of representative 
isolated human (left) and porcine (right) atrial cardiomyocytes. The scalebar (bottom right) depicts 20 μm. I and J, Representative action 
potentials (APs) recorded at 0.2 Hz in the absence or presence of A293 (200 nmol/L) are shown for isolated human (I) and porcine 
(J) atrial cardiomyocytes. K, Corresponding mean AP durations at 50% of repolarization (APD50) and 90% repolarization (APD90) 
at baseline and after A293 application (human: n/N=9/5, porcine: n/N=5/4). L, Mean relative APD50 and APD90 values after TASK- 1 
inhibition with 200 nmol/L A293 (human: n/N=9/5, porcine: n/N=5/4). Data are expressed as mean±SEM. *P<0.05, **P<0.01, ***P<0.001 
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A293 Facilitates Cardioversion in a 
Porcine Model of Acute Paroxysmal AF
A porcine model of acute paroxysmal AF was employed 
to evaluate whether A293- induced AERP prolongation 
has antiarrhythmic effects. Following jugular vein prep-
aration, diagnostic electrophysiology catheters were 
placed under fluoroscopic guidance in the upper right 
atrium and at the right ventricular apex position. AF was 
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cycle length, duration of 2–8 seconds). Upon induc-
tion of AF, the atrial rhythm was monitored for 5 min-
utes to confirm the stability of the AF episode. Pigs 
that remained in AF after this 5- minute period were 
subjected to treatment with either A293 or the vehi-
cle controls (Figure 5A). In the vehicle control group, 
only 2 of 8 spontaneous conversions were observed 
(n=8 pigs). In contrast, a cardioversion rate of 100% 
(n=5 pigs) was documented after intravenous appli-
cation of A293 (Figure 5B). Pharmacologic cardiover-
sion with A293 yielded cardioversion times of 177±63 
seconds, differing significantly from that of the control 
group (P=0.0034, Kruskal–Wallis test) as visualized in 
Figure 5C.
Computational Modeling of the A293 
Effects on Atrial Electrophysiology in a 
Single- Cell and a Tissue Model
To assess the causal role of TASK- 1 current inhibition 
in the termination of AF, we performed computational 
modeling at the single- cell and 2- dimensional tis-
sue levels. Therefore, the Courtemanche–Ramirez–
Nattel model of human atrial electrophysiology29 was 
extended by TASK- 1.10 A human model of atrial elec-
trophysiology was chosen, first, because no porcine 
electrophysiological model is available and, second, 
because it integrates a translational aspect into this 
study. In Figure 6A, simulated APs of the atrial car-
diomyocyte model are depicted at four BCLs without 
the addition of A293 (solid line) and with a full block of 
TASK- 1 channels by A293 (dashed line). The model 
was adjusted to reproduce the prolongation of the 
AERP due to A293 at 3 different BCLs (Figure 6A): 
from 157 to 173.6  ms for a BCL of 300  ms; from 
173.7 to 194.1  ms for a BCL of 400  ms; and from 
185.9 to 209.1 ms for a BCL of 500 ms. The other 
BCL- dependent prolongations of the action poten-
tial duration (APD) were predicted by the model. 
At a BCL of 200  ms, the model predicted a drug- 
induced prolongation of the APD by 12.6  ms (from 
136 to 148.6 ms, purple line in Figure 6A). At BCLs 
of 1000  ms, the APD was prolonged by 27.1  ms 
(from 208.6 to 235.7  ms, red line in Figure  6A). In 
Figure 6B, the APD90 is visualized depending on the 
concentration of A293 (IC50 of 100  nm) at 4 differ-
ent BCLs. Boxplots depicting APD90 values obtained 
from patch clamp experiments performed on human 
atrial cardiomyocytes (Figure 2K and 2L) under con-
trol conditions and after application of 200  nmol/L 
A293 are compared with our computational model 
data. Finally, the predicted relative change in APD90 
is visualized as a function of the A293 concentration 
in Figure 6C. Notably, the highest level of relative APD 
prolongation by A293 was observed at high BCLs 
(Figure 6C).
Finally, the antiarrhythmic potential of TASK- 1 current 
inhibition was investigated in multicellular tissue sim-
ulations. A simplified left atrial geometry consisting of 
a 2- dimensional spherical surface with a diameter of 
5 cm and 5 orifices representing the 4 pulmonary veins 
and the mitral valve (see Figure 6D, black spheres) was 
employed. The tissue simulation was started with 1 ro-
tational activity and in the absence of TASK- 1 current 
inhibition by A293. The initial rotor was simulated for 
10 seconds with different tissue conductivities, result-
ing in differing conduction velocities. Subsequently, 5 
seconds was simulated for each conductivity value, 
either in the presence or absence of TASK- 1 current 
inhibition by A293. We investigated the range in which 
Figure 3. Administration of A293 does not alter surface ECG parameters of healthy control pigs.
A, Representative surface ECG recordings of an anesthetized pig under baseline conditions (left) and 20 min after i.v. administration 
of A293 at 1 mg/kg body weight (right). The scale bar, provided as insert (bottom right), indicates 100 ms. B, RR intervals, P wave 
durations, PQ intervals, QRS durations, QT intervals, and QTc intervals of pigs treated with A293 display no significant differences to 
baseline conditions (n=5 pigs; n.s., no statistically significant difference in Wilcoxon matched- pairs tests). aVF indicates augmented 
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Figure 4. A293 selectively prolongs atrial effective refractory periods (AERPs).
A, Perioperative view after surgical jugular vein preparation and placement of 2 introducer sheaths into the right internal 
jugular vein. B, Intraprocedural fluoroscopy showing a quadripolar diagnostic catheter in the high right atrium position 
and another quaripolar diagnostic catheter in the right ventricular apex. C through G, Atrial (AERPs) as well as ventricular 
effective refractory periods (VERPs), measured at an S1 cycle length of 500 ms (C and D), 400 ms (E and F), or 300 ms G 
under control conditions or 20 minutes after intravenous administration of A293 at 1 mg/kg body weight in anesthetized 
pigs (n=4 pigs each; P values are indicated as inserts). H, Application of A293 resulted in a significant AERP- prolongation 
whereas VERPs remained unchanged. Data are presented as mean±SEM. *P<0.05; **P<0.01 for Student t tests.
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tissue conductivities A293 could eliminate the rotor. The 
results of the tissue simulations at a conductivity of 1.0 
S/m (corresponding to a plane wave conduction veloc-
ity of 80 cm/sec at a BCL of 1000 ms) are shown in 
Figure 6D through 6F (Videos S1 through S3). The high-
est conductivity value at which persistent reentry could 
be stopped by A293 was at 1.2 S/m (equal to 90 cm/
sec). Larger conductivity values led to termination even 
without the drug. The model predicted that the lowest 
conductivity at which the drug stopped the arrhythmia 
was 0.95 S/m (resulting in a plane wave conduction ve-
locity of 77 cm/s at a BCL of 1000 ms). For lower con-
ductivity, the model persisted always in reentry.
Thus, model simulations support the antiarrhythmic 
effects of TASK- 1 inhibition. Further, multicellular tis-
sue modeling predicted that the antiarrhythmic effect 
of TASK- 1 inhibition by A293 was strongly dependent 
on the tissue conductivity and the resulting conduction 
velocity.
DISCUSSION
Current antiarrhythmic AF treatment is limited by sub-
optimal effectiveness and often causes adverse side 
effects.1,3 The development of more effective therapies 
Figure 5. A293 facilitates cardioversion in a porcine model of paroxysmal atrial fibrillation (AF).
A, After induction of AF by right atrial burst- stimulation in anesthetized pigs, the atrial rhythm was monitored for 5 minutes. When 
AF persisted over this 5- minute period, A293 or the respective solvent control was administered. Cardioversion was monitored up to 
10 minutes after drug administration. B, Percentage of cardioversions to sinus rhythm (SR) during the 10- minute observation interval 
in the solvent control (Control) and the A293 treatment group (A293). C, Time to conversion to SR in the solvent control (Control) and 
the A293 treatment group (data are presented as medians; whiskers indicate interquartile ranges for n=5 to 8 individual experiments; P 
value was obtained from Kruskal–Wallis test). AF indicates atrial fibrillation; aVF indicates the surface ECG lead aVF; HRA, intracardiac 
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is needed to increase quality of life by reducing the 
symptoms and hospitalizations associated with AF. 
Atrial selectivity is an important aim in the development 
of novel antiarrhythmic approaches.34 In the human 
heart, TASK- 1 channels are predominantly expressed 
in the atria and might therefore represent a promising 
novel target for atrial- specific AF therapy.10,12
Protein sequences of human and porcine TASK- 1 
ion channel subunits share a high degree of homology. 
The pharmacologic sensitivity of porcine and human 
TASK- 1 currents to A293 was similar. In human as well 
as porcine myocardial tissue samples, TASK- 1 mRNA 
was primarily detected in the atria. The pig therefore 
represents an adequate model to study the cardiac 
role of TASK- 1. In contrast, in rodents, TASK- 1 expres-
sion is not confined to the atria, and AF- related TASK- 1 
remodeling differed from the effects observed in the 
tissue samples of AF patients.21 Finally, patch clamp 
recordings performed on native isolated atrial cardio-
myocytes confirmed comparable TASK- 1 current den-
sities in humans and pigs with a nonsignificant trend 
toward higher TASK- 1 currents in patient samples. It 
remains speculative whether this slight elevation of the 
atrial TASK- 1 currents may be linked to the underly-
ing atrial cardiomyopathy, as patients that underwent 
open heart surgery due to ischemic or valvular heart 
disease were compared with young and healthy pigs. 
Of note, human tissue samples were taken from pa-
tients with sinus rhythm without documentation of AF 
in their prior medical history and without relevant left 
ventricular dysfunction. Despite differences in APD 
under control conditions, TASK- 1 current inhibition re-
sulted in a similar prolongation of human and pig atrial 
cardiomyocyte APD. Our preclinical proof- of- concept 
trial in pigs confirmed that pharmacological TASK- 1 
inhibition by A293 prolongs atrial refractoriness with 
no effects on ventricular repolarization. ECG analyses 
further supported the absence of side effects on ven-
tricular electrophysiology. Based on a clinically relevant 
large animal model, we showed that blockade of atrial 
TASK- 1 currents exerts class III antiarrhythmic effects 
in vivo, resulting in acute cardioversion of paroxysmal 
AF episodes. This study is, to our knowledge, the first 
report demonstrating the potential of pharmacological 
TASK- 1 inhibition for acute cardioversion.
In silico model simulations mechanistically repro-
duced the antiarrhythmic effect of TASK- 1 inhibition 
in a single- cell model of human atrial cardiomyocytes. 
Both, effects of A293 on APD90 values measured in 
patch clamp experiments on human atrial cardiomy-
ocytes and antiarrhythmic effects as observed in our 
large animal experiments could be recapitulated in sil-
ico. This model could be used to create predictions for 
a wider range of experimental conditions and therefore 
provides a platform for future mechanistic and inter-
ventional studies. Of note, the strongest effects of APD 
prolongation by A293 were predicted for the longest 
BCLs, implying that tissue with A293 has a decreased 
chance to develop arrhythmia (Figure 6C).
A293 was initially developed as a KV1.5 channel in-
hibitor by Sanofi Aventis. This drug later was shown to 
exhibit a 42- fold higher affinity for TASK- 1 channels than 
KV1.5 channels.
16–18 Some proprietary data of Sanofi 
Aventis were published by Wirth et  al in 200735: In a 
small series of large animal experiments, A293 (there 
known as AVE1231) prolonged AERPs.17,35 Although a 
different route of delivery (enteral application via gastric 
tube) and another stimulation site (left atrium instead of 
right atrium) were used, Wirth et al35 reported AERP pro-
longations at different BCLs by 19 to 20.8 ms, similar to 
the results obtained in our experimental study and our 
computational single- cell model. Their finding that the 
effect of A293 on AERPs was even more pronounced 
in the Alessi goat model of tachypacing- induced arti-
ficial AF is most likely explained by AF- associated up-
regulation of TASK- 1, as KV1.5 was described to be 
downregulated in atrial remodeling.36
CLINICAL IMPLICATIONS
In addition to the atrial myocardium, TASK- 1 is ex-
pressed in human pulmonary artery smooth muscle 
cells.37 In these cells, TASK- 1 currents are crucial 
for setting the basal membrane potential and con-
secutively regulating pulmonary vascular tone.38 
Additionally, TASK- 1 loss- of- function mutations were 
identified in patients suffering from idiopathic pul-
monary arterial hypertension.39 Experimental results 
on the effects of TASK- 1 inhibition on the pulmonary 
arterial vascular tone, however, are extremely sparse 
and partially contradicting. While rats were reported to 
exhibit pulmonary arterial hypertension after chronic 
exposure to a TASK- 1 inhibitor,40 TASK- 1 knockout 
mice displayed pulmonary artery pressure and right 
ventricular pressure levels that did not differ from their 
wild- type littermates.41,42 Further studies will be neces-
sary to clarify whether pharmacologic TASK- 1 inhibi-
tion leads to pulmonary arterial hypertension and to 
explore its long- term efficacy, safety, and toxicology. 
In our study, A293 treatment was well tolerated in se-
dated animals. After drug exposure, no clinical adverse 
effects were observed over a period of 3 to 5 days.
LIMITATIONS
It is, however, very important to consider that the AF 
subtype simulated in our porcine arrhythmia model is 
a relatively mild form of AF that might lack significant 
structural alterations of atrial tissue that contribute to the 
development and maintenance of arrhythmia in AF pa-
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to situations with new onset of paroxysmal AF episodes, 
they cannot be generalized to patients suffering from 
persistent AF. In the past, for instance, blockers of the 
KV1.5 channel were found to display robust antiarrhyth-
mic effects during sinus rhythm, which were significantly 
attenuated under AF conditions attributable to functional 
ion channel remodeling and structural alterations.17
Therefore, further studies will need to assess 
the performance of TASK- 1 inhibition in acute 
cardioversion of persistent AF. Further, the efficacy 
of TASK- 1 current inhibition in rhythm control of per-
sistent AF remains to be elucidated. Finally, as AF- 
related upregulation of TASK- 1 currents was reported 
in human10,11 as well as in porcine disease models,43,44 
one could speculate that TASK- 1 inhibition exerts an-
tiarrhythmic potential, especially in patients with per-
sistent AF. The fact that human atrial cardiomyocytes 
display slightly higher TASK- 1 current densities than 
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those of pigs may indicate a pronounced antiarrhyth-
mic efficacy of TASK- 1 current inhibition in patients. 
Furthermore, remodeling of TASK- 1 channels differs 
between AF subgroups with preserved or reduced 
left ventricular ejection fraction,11 providing a mech-
anistic basis for an individualized pharmacotherapy 
of AF.
The sample sizes used in this study were relatively 
small because of regulations on animal protection. 
It was reported that members of the K2P family are 
susceptible to a wide range of narcotics. Therefore, 
propofol was used as an anesthetic agent in this study 
because its effect on TASK- 1 had been ruled out in 
previous studies.44
CONCLUSIONS
In conclusion, pharmacologic TASK- 1 inhibition by 
A293 prolongs atrial refractoriness with no effects on 
ECG intervals and ventricular repolarization. Therefore, 
blockade of atrial TASK- 1 currents exerts class III an-
tiarrhythmic effects in vivo, resulting in acute cardio-
version of paroxysmal AF episodes. Finally, our results 
confirmed the role of TASK- 1 as a promising drug tar-
get in AF and might therefore promote the translation 
of a novel, mechanism- based antiarrhythmic paradigm 
into clinical practice.
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Figure 6. Computational modeling of the effect of A293 on atrial electrophysiology in single- cell and tissue model.
A through C, Single- cell model simulations of actions potentials and APD for different BCL values and A293 concentrations. A, 
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